A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

NCT07173595 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Hematologic Malignancies

Interventions

DRUG: QLS2309

Sponsor

Qilu Pharmaceutical Co., Ltd.